Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche, Eli Lilly get FDA nod for new Alzheimer's blood test

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Roche and Eli Lilly have received FDA approval for a new blood test for Alzheimer's disease, which will also be offered by Labcorp and Quest Diagnostics following earlier CE mark certification.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 5 sources have reported it between 24 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

You need to act now if you develop diagnostic tools for neurodegenerative diseases since FDA approval for these blood tests opens US clinical markets widely. Labs like Labcorp and Quest are early distributors — partner or compete with them fast.

◆ Coverage

5 sources · first reported 24 Aug 2026 · latest 25 Aug 2026

◆ Related on Wire

◆ Topics

DiagnosticsalzheimersdiagnosticsFDA-approvalblood-testRocheEli-Lilly